Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Buzzing Indian M&A/IPO Counter In 2016?

This article was originally published in Scrip

Executive Summary

2016 could see an uptick in M&A deal flow in India and more than half a dozen healthcare/pharma firms may consider going public, buoyed by a clutch of successful recent IPOs, according to experts in the deal advisory/private equity space.

You may also be interested in...



Asia Life Sciences IPO Landscape: China, Hong Kong March Ahead But Watch India

Four key Asian markets witnessed nearly 200 life science company listings over the past 10 years, with China dominating the scene and expected to stay ahead, along with Hong Kong, for the foreseeable future. But India could prove a new contender over time as firms move up the value chain, a new report shows.

M&A Trends: The Growing Indian Appetite

A recent round table on pharma industry trends has highlighted the hunger of cash-rich Indian firms for acquiring companies with niche portfolios in regulated markets including the US. Innovator companies shedding their generic units also present significant opportunities for Indian firms. Both trends are expected to build amid apparent Indian interest in the Teva-Allergan divestiture in Europe.

CEO Pay Packages Expand in India But Ratio To Employee Earnings Hurts

Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.

Topics

UsernamePublicRestriction

Register

SC064088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel